tag:www.regimmune.com,2008://1 2008-05-06T21:10:11Z 免疫制御技術を利用して社会に貢献するバイオテック企業 Movable Type 3.31-ja tag:www.regimmune.com,2008://1.49 2008-05-06T05:05:45Z 2008-05-06T21:10:11Z

REGiMMUNE Raises $8,000,000 in Series B Financing

regimmune こちらから]]> email contact]]> tag:www.regimmune.com,2008://1.47 2008-04-17T21:53:01Z 2008-04-18T22:25:00Z

RGI-2001 program was introduced on Nikkei Business Paper

admin キリンファーマとのライセンス契約に基づきKRN7000（αガラクトシルセラミド(αGalCer)の一種)と呼ばれる糖脂質の一種を含むリポソーム製剤による免疫制御技術です。reVax技術は独立行政法人理化学研究所（理研） 免疫・アレルギー総合研究センター、石井保之博士により開発された基本技術をであり、当社は理研より独占的なライセンスを受けています。 　 　reVax技術を用いることにより、生体防御機能としての免疫機能を維持したまま、特定の免疫反応だけを抑制することが可能であり、これまでの免疫抑制剤の問題であった免疫機能の全体的低下を防ぐことが可能です。免疫機能が失われた場合には感染、癌の発生・進行が起こる可能性が高くなりますが、この技術ではこういった問題を解決することが可能です。 　 　　我々は薬効試験および製造技術の確立、毒性試験の一部を終えており、早期の米国治験申請目指して現在前臨床試験を行っております。 　 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから]]> tag:www.regimmune.com,2008://1.46 2008-02-07T03:20:16Z 2008-02-07T04:06:06Z

Immune Tolerance

admin National Institute of Allergy and Infectious Diseases (NIAID) of National Institutes of Health (NIH) ]]> National Institute of Allergy and Infectious Diseases (NIAID) of National Institutes of Health (NIH) ]]> tag:www.regimmune.com,2008://1.45 2008-01-31T15:00:00Z 2008-02-22T20:27:39Z

REGiMMUNE Closes First Tranche of Series B Financing

admin reVaxテクノロジーの強化に充当される予定です。 　 このような厳しいファイナンス環境においても、このような順調な資金調達をおこなえたのは、当社の技術力、順調な開発の進捗、それを支えるチーム構築に高い評価をいただいた結果であると考えております。皆様のご期待に沿うべくさらに事業を進捗させてまいります。 　 なお、当社はシリーズＢの追加募集を行っていく予定です。 　 参考：日経ＢＰ社ニュース 　 　 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから]]> Mountain View, CA and TOKYO – Feb 1, 2008 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised a total of $6 million U.S. in a Series B venture capital financing from new and existing investors. The original lead investor NIF SMBC Ventures Co., Ltd. led the round, with the participation of new investors CSK Venture Capital Co., Ltd.; GH Holdings K.K..; Resona Capital Co.,Ltd.; AC Ventures Co., Ltd. and Friendly Partners Co., Ltd. Also participating in this financing are existing investors Japan Asia Investment Co., Ltd.; Yasuda Enterprise Development Co., Ltd.; New Business Investment Co., Ltd.; and Fund Creation Co., Ltd. REGiMMUNE plans to keep this round open for several months for additional venture firms interested in becoming part of the syndicate. Proceeds from the financing will be used to complete the IND filing for RGI-2001 and to expand the company’s proprietary technology platform, reVax (reverse vaccination). "We are very pleased to have the continuing support of our initial investors and to welcome our new investors," stated Haru Morita, President and Chief Executive Officer. "We are happy to receive this current commitment from investors, in spite of the poor market conditions all over the world. We believe this is proof of investor confidence in our technology, our progress of development and the credibility of the management team." About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company’s proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. US MEDIA CONTACT FOR REGiMMUNE: Debra Bannister 530 676-8001 debra@regimmune.com tag:www.regimmune.com,2008://1.44 2008-01-27T15:00:00Z 2008-04-04T01:50:13Z

REGiMMUNE Licensed Immunoregulatory Compound from KIRIN Pharma

admin こちらから]]> MOUNTAIN VIEW, CA and TOKYO – Jan 28, 2008 -- REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that the company recently signed a license agreement with Kirin Pharma Company, Limited for the exclusive worldwide rights to use Kirin’s clinical stage compound, KRN7000, formulated with a liposome. KRN7000 is a biological response modifier that belongs to a chemical class called alpha-galactosylceramides, or alpha-GalCer. Originally isolated from a marine sponge, this compound was first investigated as a potential anti-cancer compound. KRN7000 was later found to act as a ligand for natural killer T (NKT) cells, exhibiting potent immunomodulatory activities. The compound has been extensively studied, with more than 1,000 scientific research papers published to date. Kirin Pharma had conducted clinical studies of KRN7000 for the treatment of cancer, as well as for hepatitis B and hepatitis C. By incorporating KRN7000 into a specific liposomal formulation, REGiMMUNE has developed a proprietary, immunomodulatory platform technology, reVax, applicable to a broad range of immune disorders. reVax technology uniquely induces antigen-specific immune suppression via induction of regulatory T cells (or Tregs), a T cell subset that plays a central role in controlling immune responses to self-antigens and pathogens. REGiMMUNE’s reVax is the first and only available technology to pharmacologically enhance the function of Tregs. Induced by reVax, Tregs downregulate pathologic immune responses and maintain a fine balance between immune activation and immune suppression to a given antigen. Further, because of the antigen-specific manner of immune suppression, reVax products are anticipated to maintain the body’s normal immune function. REGiMMUNE applies reVax technology to develop drugs for the treatment of various immune disorders, including allergy, such as cedar pollen allergy, graft versus host disease (GvHD) associated with bone marrow transplantation, solid organ transplantation, and autoimmune diseases. In addition to pursuing the company’s in-house drug development programs, REGiMMUNE is actively seeking collaboration partners to apply its reVax platform technology to partner’s antigens/ allergens or its field of interest. About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company’s proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. 　 US MEDIA CONTACT FOR REGiMMUNE: Debra Bannister 530 676-8001 debra@regimmune.com tag:www.regimmune.com,2008://1.48 2008-01-24T20:52:38Z 2008-05-06T21:47:08Z

Robert NEGRIN, M.D. appointed to Scientific and Clinical Advisor

regimmune こちらから]]> email contact]]> tag:www.regimmune.com,2007://1.43 2007-10-05T11:24:04Z 2007-11-06T19:44:11Z

Dr.Reiko NAMIKAWA appointed to VP, Strategic Development Planning

admin スタンフォード大学医学部、アービン・ワイスマン(Irving_Weissman)教授のラボに留学され、そのラボで開発されたSCID-huマウス技術をもとに設立されたSyStemix社(1989年 NASDAQ上場、後にNovartis社に買収）の創業メンバーとして活躍をされました。その後、Dynax研究所(現-Plough Biopharma in Palo Alto)に移られ、SCID-hu技術の新たな応用についてご研究をされました。さらにBioGenomics, Inc.,の創業、GeneTrol Biotherpeutics, Inc.の経営にＣＳＯとして携わられたのちにコンサルティングに身を転じ、Clearview Projects, Inc.社のExecutive Director, Science & Medicineとしてご活躍をされました。 　 　 レグイミューンにおいては執行役員、戦略開発企画担当として、開発戦略の立案およびその導入を担当することになります。これにより当社の開発オペレーションのより一層の機能強化が実現するとともに、2008年に予定される臨床試験に向けての開発の推進を期待できると考えております。 　 　 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから]]> email contact ]]> tag:www.regimmune.com,2007://1.42 2007-08-07T03:08:43Z 2007-10-24T11:40:20Z

REGiMMUNE Receives Grant Award from METI

regimmune 平成19年度「地域新規産業創造技術開発費補助事業及び地域資源活用型研究開発事業」に採択されました。 本事業は、地域において新産業・新事業を創出し、地域経済の活性化を図るため、中堅・中小企業による新分野進出やベンチャー企業による新規創業といった、リスクの高い実用化技術開発を支援することを目的として運営されている事業です。当社事業は独立行政法人理化学研究所免疫・アレルギー総合研究センターで生み出された技術を基に医薬品としての実用化を目指して行われているものです。今回、本件補助事業に採択されたことは当社の優れた技術が認められたと同時にそれによる開発パイプラインであるスギ花粉症治療薬に大きな期待が寄せられている証であると考えます。当社はこうした期待に応えるべく事業の推進に努めていく所存です。 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから ]]> Mountain View, Calif. and Tokyo, Japan – August 7, 2007 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today it has been awarded a grant from the Japanese Ministry of Economy, Trade and Industry (METI). REGiMMUNE received the grant under the METI-sponsored Regional New Consortium Projects/New Industry Creative-Type Technology R&D Promotion Programs, which is intended to promote new industries and new small businesses in Japan. The one-time grant will provide a portion of the funds for the company’s development of its immune regulatory therapeutics for cedar allergy. The METI program is similar to the Small Business Innovation (SBIR) grant programs from U.S. government agencies such as the National Institutes of Health and the Centers for Disease Control. “This award validates the importance of REGiMMUNE’s reVax technology to address the unmet need for cedar allergy treatments, which is an urgent issue in Japan,” said Haru Morita, CEO and President of REGiMMUNE. “We are pleased that METI has recognized the potential of our technology with this generous grant.” About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company’s proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. US MEDIA CONTACT FOR REGiMMUNE: Debra Bannister 530 676-8001 debra@regimmune.com tag:www.regimmune.com,2007://1.41 2007-03-22T06:19:26Z 2007-04-23T07:47:11Z

REGiMMUNE established broad collaboration with RIKEN

regimmune 理研ベンチャー」となりました。 理研ベンチャー制度は理研で生み出された研究成果の迅速な普及と実用化に繋げるべく、スピンオフベンチャーを支援する制度です。 認定によって以下の支援措置を受けられることになります。 (1) 特許権等の実施許諾における優遇措置 ・ 理研ベンチャー認定期間中、当該ベンチャー以外に実施権を許諾しないこと ・ 再実施権を認めること ・契約一時金の免除をおこなうこと (2) 共同研究における優遇措置 ・ 理研との共同研究において、必要なスペース、研究設備等の使用を認めること (3) 兼業及び出向の許可 など すでに2007年9月に基本技術のライセンス契約を締結しておりますが、本制度によって更なる連携の強化とそれに伴う開発の推進が期待されると考えております。 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから]]> REGiMMUNE Establishes Broad Collaboration with RIKEN MOUNTAIN VIEW, CA and TOKYO -- Mar 22, 2007 -- REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has enter into an Intellectual Property and Industry-Academia Collaboration Program with RIKEN, a Japanese public research institute supported by the government. This arrangement provides REGiMMUNE with a number of benefits including exclusive licenses to certain RIKEN patents. "We are very pleased to establish this broad collaboration with RIKEN," stated Haru Morita, President and Chief Executive Officer. "It is really encouraging for us to have such continuous support and strong commitment from RIKEN, where the original technology was developed. This closely connected relationship will boost our development competitiveness." About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company's proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. About RIKEN The mission of RIKEN is to conduct comprehensive research in science and technology (excluding only the humanities and social sciences) as provided for under the "RIKEN Law," and to publicly disseminate the results of its scientific research and technological developments. RIKEN carries out high level experimental and research work in a wide range of fields, including physics, chemistry, medical science, biology, and engineering, covering the entire range from basic research to practical application. RIKEN was first organized in 1917 as a private research foundation, and reorganized in 2003 as an independent administrative institution under the Ministry of Education, Culture, Sports, Science and Technology. US MEDIA CONTACT FOR REGiMMUNE: Debra Bannister 530 676-8001 debra@regimmune.com ]]> tag:www.regimmune.com,2007://1.40 2007-03-12T05:19:27Z 2007-11-09T03:22:58Z

Access to Mountain View Office

regimmune ●California State Route 237Wより 　　　MAUDE AVE exit を MIDDLEFIELD RD. 方面へ 　　　MAUDE AVE. で右折 　　　LOGUE AVE.　で左折 　　　BIＣ館内 ●サンフランシスコ国際空港より 　　　US-101を南方向へ 　　　ELLIS STREET exit- EXIT 397 を MOFFETT SOUTH GATE.方面へ 　　　ELLIS ST.　へ 　　　E MIDDLEFIELD RD.で左折 　　　LOGUE AVE.で左折 　　　ＢＩＣ館内 320 Logue Ave., Mountain View, CA 94043, USA +1.650.938.6530 ]]> From California State Route 237W Take the MAUDE AVE exit toward MIDDLEFIELD RD. Turn RIGHT onto MAUDE AVE. Turn LEFT onto LOGUE AVE. Find BIC at 320 Logue Ave From San Francisco International Airport Merge onto US-101 S. Take the ELLIS STREET exit- EXIT 397- toward MOFFETT SOUTH GATE. Merge onto ELLIS ST. Turn LEFT onto E MIDDLEFIELD RD. Turn LEFT onto LOGUE AVE. Find BIC at 320 Logue Ave 320 Logue Ave., Mountain View, CA 94043, USA +1.650.938.6530 ]]> tag:www.regimmune.com,2007://1.39 2007-03-08T08:12:37Z 2007-03-08T08:31:30Z

Featured in the issue of the Biotechnology Japan.

regimmune レグイミューン、B-Bridge、JETRO、 米国のインキュベーターに実験室を開設、臨床試験準備の一環から 本ラボの開設により、インハウスでの実験が機動的に行えるようになります。これまで通り、専門的なコントラクト先を活用すると共に、本ラボの開設によって、よりいっそう開発スピードを早める所存です。 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから]]> Featured in the issue of the Biotechnology Japan. (Sorry, this article is only in Japanese.) tag:www.regimmune.com,2007://1.38 2007-02-21T08:22:02Z 2007-10-23T06:26:25Z

REGiMMUNE Announces Series A Financing

regimmune レグイミューン、5億円の資金調達を完了 照会先： 経営企画室長/管理部長 網崎裕子 03-3456-0820 ご照会はこちらから]]> About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company's proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. US MEDIA CONTACT: Debra Bannister 530 676-8001 email contact]]> tag:www.regimmune.com,2007://1.37 2007-02-01T08:03:57Z 2007-05-14T07:30:13Z

Relocation of US Office

regimmune こちらから]]> About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company's proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan. The US subsidiary is located at 320 Logue Ave., , Mountain View, CA 94043. Telephone: 650.938.6530. ]]> tag:www.regimmune.com,2007://1.36 2007-01-26T14:41:07Z 2007-02-22T08:20:11Z

REGiMMUNE Announces Appointment of Shirley Clayton to Board of Directors

regimmune こちらから]]> About REGiMMUNE REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company's proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. US MEDIA CONTACT: Debra Bannister 530 676-8001 email contact]]> tag:www.regimmune.com,2006://1.34 2006-11-29T11:41:14Z 2007-05-14T07:44:14Z

REGiMMUNE Announces Appointment to the Board

regimmune こちらから]]> here. ]]>